作者: Fred J. Witjes , Frans M.J. Debruyne , Pilar Fernandez Del Moral , A.D.H. Geboers
DOI: 10.1016/0090-4295(89)90037-X
关键词:
摘要: Ketoconazole high dose (H.D.) effectively reduces the testosterone production in both adrenals and testes. Its use management of (metastatic) prostate cancer has been advocated. Even relapsing patients, after previous hormonal therapy, ketoconazole H.D. could be value. Twenty-eight whom 15 were evaluable at three months, have treated with As expected, objective response was seen only a small number patients followed up till nine months. Subjective improvement, however, noticed majority symptomatic patients. The side effects toxicity therapy remain major limitation for ketoconazole, it as first line treatment or